SUBSEQUENT EVENT (Details) - Subsequent events - fostamatinib - Grifols $ in Millions |
1 Months Ended |
|---|---|
|
Jan. 31, 2020
USD ($)
| |
| Subsequent Event [Line Items] | |
| Collaborative payment received | $ 20.0 |
| Creditable advance royalty payment | |
| Subsequent Event [Line Items] | |
| Collaborative payment received | 2.5 |
| EMA approval of fostamatinib | |
| Subsequent Event [Line Items] | |
| Collaborative payment received | $ 17.5 |
| X | ||||||||||
- Definition Cash received from collaborators during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|